Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures by Schroeder, M.P. et al.
1Scientific RepoRts |          (2019) 9:4188  | https://doi.org/10.1038/s41598-019-40786-1
www.nature.com/scientificreports
Integrated analysis of relapsed 
B-cell precursor Acute 
Lymphoblastic Leukemia identifies 
subtype-specific cytokine and 
metabolic signatures
Michael p. schroeder1, Lorenz Bastian  1,2,3,13, Cornelia eckert2,3,4, Nicola Gökbuget2,3,5, 
Alva Rani James1,2,3, Jutta ortiz tanchez1, Cornelia schlee1, Konstandina Isaakidis1, 
Björn Häupl2,3,5, Katharina Baum6, oscar Arturo Migueles Lozano6, Khouloud Kouidri5, 
Kuan-ting pan  7, Henning Urlaub7,8, stefan schwartz1, thomas Burmeister1, 
Arend von stackelberg2,3,4, Dieter Hoelzer5, Heike Pfeiffer5, Michael A. Rieger2,3,5, 
stefanie Göllner9, thomas oellerich2,3,5, Martin Horstman10, Martin schrappe11, Jana Wolf6, 
Renate Kirschner-schwabe  2,3,4, Monika Brüggemann12, Carsten Müller-tidow9, 
Hubert serve  2,3,5, Martin Neumann1,2,3 & Claudia D. Baldus1,2,3,12
Recent efforts reclassified B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) into more refined 
subtypes. Nevertheless, outcomes of relapsed BCp-ALL remain unsatisfactory, particularly in adult 
patients where the molecular basis of relapse is still poorly understood. to elucidate the evolution of 
relapse in BCp-ALL, we established a comprehensive multi-omics dataset including DNA-sequencing, 
RNA-sequencing, DNA methylation array and proteome MAss-spec data from matched diagnosis and 
relapse samples of BCP-ALL patients (n = 50) including the subtypes DUX4, Ph-like and two aneuploid 
subtypes. Relapse-specific alterations were enriched for chromatin modifiers, nucleotide and steroid 
metabolism including the novel candidates FPGS, AGBL and ZNF483. the proteome expression 
analysis unraveled deregulation of metabolic pathways at relapse including the key proteins G6PD, 
TKT, GPI and PGD. Moreover, we identified a novel relapse-specific gene signature specific for DUX4 
BCp-ALL patients highlighting chemotaxis and cytokine environment as a possible driver event at 
relapse. this study presents novel insights at distinct molecular levels of relapsed BCp-ALL based on a 
comprehensive multi-omics integrated data set including a valuable proteomics data set. the relapse 
specific aberrations reveal metabolic signatures on genomic and proteomic levels in BCP-ALL relapse. 
Furthermore, the chemokine expression signature in DUX4 relapse underscores the distinct status of 
DUX4-fusion BCP-ALL.
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The dismal prognosis of relapsed B cell precursor Acute Lymphoblastic Leukemia (BCP-ALL) warrants for novel 
and more specific therapeutic approaches1,2. Genetic lesions in relapsed BCP-ALL remain the prerequisite for 
personalized treatment approaches, preferably in the minimal residual disease (MRD) setting3. Next genera-
tion sequencing (NGS) has advanced the genetic identification of disease-contributing aberrations, which may 
become targets of new approaches. In Ph-like BCP-ALL, clinical evidence has emerged that patients with these 
lesions might specifically benefit from treatment with tyrosine kinase inhibitors (TKIs)4–6. Besides Ph-like ALL, 
other molecularly defined subgroups have been unraveled, but yet no targeted therapeutic approaches have been 
systematically explored7–9. For now, molecular studies predominantly focused on pediatric ALL and on molecular 
alterations at initial diagnosis7,10–13.
An important prognostic factor in pediatric and adult relapsed ALL is the duration of first remission14,15. 
Identified differences in the molecular make-up of early and late pediatric relapses are CDKN2A/2B deletions, 
which are more frequent in early relapses, and NT5C2 mutations occurring primarily in early relapses/on treat-
ment3,16. Gene expression variations associated with time to relapse as well as a great diversity in the IG/TCR gene 
rearrangement repertoire in early relapse have been reported17–20, suggesting a different molecular portrait and a 
distinct pattern of clonal evolution in early versus late ALL relapse.
Clonal evolution studies have revealed mutations emerging in subclones, different from the dominant diag-
nostic clone21,22. The first comprehensive study, which analyzed relapse-specific genetic alterations, identified 
recurrent mutations in CREBBP, a transcriptional corepressor23. Other studies identified NT5C2, RAS and PRPS1 
mutations emerging in novel clones in relapsed pediatric ALL16,24,25. Particularly NT5C2 mutations have been 
described to emerge as a response to chemotherapy16. The heterogeneity of cancer makes it likely that additional 
mutated driver genes will be discovered in sub-entities that have not yet been studied in depth26.
In contrast to the availability of detailed genomic data generated on NGS platforms, proteomic characteriza-
tion of BCP-ALL remains largely unexplored. Recent insights though highlight the relevance of proteomic and 
metabolomic analyses demonstrating the gatekeeper function of the Pentose-Phosphate pathway (PPP) in PAX5- 
and IKZF1-driven BCP-ALL mouse models and other model systems27. Yet unbiased proteomics on primary 
samples from relapsed BCP-ALL patients combined with matched multi-omics data are lacking.
Thus, here we combined pediatric and adult relapsed BCP-ALL in one dataset for a comprehensive approach, 
analyzing DNA methylation, RNA- and exon-sequencing and proteome expression data obtained from the same 
samples in order unravel relevant pathway alterations. This multi-omics characterization of a combined cohort 
of 50 matched triplicate samples at diagnosis, remission and relapse highlight novel insights in key mechanisms 
of resistance.
Material and Methods
patients samples. All patients were treated in population based German study trials (GMALL for adult 
and COALL/BFM for pediatric patients). All patients gave written informed consent to participate in these trials 
according to the Declaration of Helsinki. This study was approved by the ethics board of Charité, Berlin. Patients 
sample triplets retrieved at initial diagnosis (ID), complete remission (CR) and relapse (REL) excluded patients 
with known fusion genes (BCR-ABL1, KMT2A-AFF1, ETV6-RUNX1). CR samples were used as germline con-
trols for whole exome and panel sequencing. Pediatric and adult patients treated on pediatric inspired intensive 
protocols were categorized into early and late relapse, based on a cut-off at 700 days to relapse.
Nucleic acid preparation. RNA isolation was performed using Trizol reagent (Life Technologies, Grand 
Island, NY). RNA integrity numbers greater than seven were required. Samples from ID and REL were used for 
RNA-seq. DNA was extracted using unstranded Allprep extraction (Qiagen, Hilden, Germany) and used for 
WES, panel-sequencing and methylation arrays. For WES, samples from ID, CR, and REL were processed.
Sequencing was performed on an Illumina HiSeq4000 platform. For Whole Exome Sequencing (WES) three 
samples/lane were proceeded using Low input Exome-Seq Human v5 + UTRs (Agilent, Santa Clara, California) 
with an average coverage of 141.6 Mio mapped reads/sample (MMRS). Panel-sequencing was performed using 
a customized biotinylated RNA oligo pool (SureSelect, Agilent, Santa Clara, California) to hybridize the target 
regions comprising 362 kbp on a HiSeq2000. We obtained an average coverage of 30.1 MMRS. For RNA-seq, six 
samples per lane were sequenced with an average 64 MMRS. All sequences were aligned to the human genome 
build GRCh37.7528 using the bcbio-nextgen pipeline v0.9.1a-7da8dce and STAR-aligner29 respectively.
Protein expression was obtained by using an UltiMate 3000 RSLCnano HPLC system coupled online to a Q 
Exactive Plus mass spectrometer. A detailed protocol is available in Supplementary Methods.
Primary data are available at the European Genome-phenome Archive (EGAS00001002856).
Somatic mutations were detected using the bcbio-nextgen pipeline Mutect, Freebayes, Vardict, Varscan, copy 
number variations were called with CNVkit and copywriteR; Pyclone and Schism were used for the clonality 
analyses. Fusion genes were detected with defuse and FusionCatcher and expression quantification were obtained 
with Stringtie; differential expression analysis was performed with limma. Differential methylation analysis has 
been performed with bumphunter. Statistical Tests were carried out two-tailed and if not indicated otherwise in 
Supplementary Methods30–38.
ethics approval and consent to participate. All patients gave written informed consent to participate in 
these trials according to the Declaration of Helsinki.
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Results
Genomic characterization of adult and pediatric relapsed patients. We analyzed 50 BCP-ALL 
patient trios, initial diagnosis (ID), complete remission (CR) and relapse (REL), including 26 pediatric and 24 
adult patients lacking recurrent cytogenetic rearrangements as assessed by the conventional diagnostic workup 
(BCR-ABL1, KMT2A-AFF1, ETV6-RUNX1, TCF3-PBX1). We used the WES data of the CR samples as germline 
control for the mutation and copy number analyses. The mutational and copy number status were examined by 
WES and targeted panel sequencing; expression profiles and fusion-genes were obtained via RNA-sequencing and 
the methylation status by Illumina DNA Methylation arrays.
We profiled the recurrently mutated genes and targets of copy number alterations (CNA). Epigenetic reg-
ulators (CREBBP, KMT2D, EZH2; Table S1a,b; Fig. S1) were predominantly altered in adult patients. In con-
trast, mutations in genes related to the activity of conventional ALL therapy elements (NR3C1 - glucocorticoid 
response, NT5C2 - response to purine analogues) were only observed in pediatric patients (Table 1). Patients 
relapsing early had more alterations in CDKN2A/B and in PTPRD, whereas patients relapsing late showed more 
IKZF1 alterations (Table 1). Genes preferentially subjected to homozygous deletions were VPREB1 (n = 6), SH2B3 
(n = 4), and ETV6 (n = 2). The SH2B3 deletions occurred exclusively in pediatric samples.
transcriptome and methylome signatures classify samples into BCp-ALL subtypes. We clas-
sified the samples into known molecular BCP-ALL subtypes based on distinct mRNA expression signatures 
accompanied by specific gene fusions, mutations and a defined methylation status (Fig. S2a–c; Supplementary 
Table S2a–d). This subgroup allocation remained stable from diagnosis to relapse. 12 patients (24 samples), 
including 10 pediatric, were assigned to the DUX4-IGH fusion (short: DUX4) subtype, 12 patients (24 samples) 
were classified as Ph-like and 14 patients (28 samples; 4 pediatric, 10 adult) had an aneuploid karyotype defined 
by 3 or more whole chromosomes affected by loss of heterozygosity (LOH; loss of chromosome or copy-neutral 
LOH) or other hyperdiploidies (Table S3a). Of these 14 aneuploidy cases, 4 patients had TP53 mutations accom-
panied by a masked low-hypodiploid karyotype (LH) including gains in chromosomes 1 and 22 (Fig. S3). The 
remaining 10 aneuploid patients shared distinct gene methylation and expression patterns (Fig. S2a,b) and were 
classified as masked near-haploid ALL and high hyperdiploid, thus referred to as NH-HeH. NH-HeH patients 
showed a pattern of gains in chromosomes 4, 14 and 21 (Table S3a,b). The analysis of differentially expressed and 
methylated genes revealed that DUX4 and NH-HeH samples were characterized by a hypo-methylation pattern 
when compared to the remaining samples (Table S4a,b).
The remaining yet unclassified samples were grouped according to recurrent or known BCP-ALL gene fusions: 
BCL2-IGH (2 patients), EP300-ZNF384 (2 patients) MEF2D-PYGO2 (1 patient), and KMT2A-MLLT3 (1 patient). 
Six additional samples (3 patients) lacking all of the above-mentioned fusions, had mutations (n = 4) and fusions 
(n = 2) within PAX5. The seven remaining samples (3 patients, and the REL of the classified BCL2-IGH ID) could 
not be attributed to a specific subtype. Specific lesions could be observed for the different BCP-ALL subgroups: 
somatic TP53 mutations in LH patients and CRLF2 and other kinase mutations in Ph-like patients (Fig. S2c).
Clonal evolution reveals volatile and stable mutations driving relapse. To dissect patterns 
of clonal evolution, mutations were categorized into three main categories: stable (occurring both at ID and 
REL; 31% of the mutations); ID only, if a mutation was not present in REL (22.6%); REL only, if a mutation was 
acquired between ID and REL (40.9%; Fig. 1a). At relapse, a minority of mutations dropped to subclonal levels 
(1.1%), meaning under 10% variant allele frequency (VAF), or have expanded from subclonal levels into a major 
clone (4.3%).
Gene Early Relapse (ER) Patients (n = 25) Late Relapse (LR) Patients (n = 25) p-value
CDKN2B 13 deletions 2 deletions <0.01
CDKN2A 13 deletions 3 deletions <0.01
PTPRD 7 (6 deletions/1 mutation) 0 alterations <0.01
PRSS3 8 (7 deletions/1 mutation) 1 deletion 0.02
IKZF1 2 (1 deletion/1 mutation) 9 (4 mutations/3 deletions/2 double hits) 0.04
Pediatric Patients (n = 26) Adult Patients (n = 24)
NR3C1 7 (6 deletions/1 mutation) 0 alterations 0.01
CREBBP 1 deletion 7 (5 mutations/2 deletions) 0.02
KMT2D 1 mutation 6 mutations 0.05
EZH2 0 alterations 4 (2 mutations/2 deletions) 0.05
TP53 3 (2 double hits/1 mutation) 8 (3 double hits/3 mutations/2 deletions) 0.09
NT5C2 4 mutations 0 alterations 0.11
Table 1. Molecular events biased towards subgroups. Samples from early relapse (ER; time of REL <700 days) 
showed a bias towards deletions involving the CDKN2A/B locus as 13 of the 15 deletions were associated with 
an early relapse as well as mutations or copy number losses of PTPRD (7/7). Mutations and copy number losses 
of IKZF1 were observed in 9 of 11 patients with IKZF1 alterations in ID and/or REL relapsed later than 700 days 
and thus revealed a clear tendency to late relapse. NR3C1 was deleted (n = 6) and mutated (n = 1) exclusively in 
pediatric samples. Acronyms used: ER (early relapse), LR (late relapse), ID (initial diagnosis), REL (relapse).
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46% in pediatric and 58% in adult (52% overall) of the relapsed leukemia proceeded from a precursor clone 
characterized by the loss of the major clone, while maintaining a minor clone. 46% in pediatric and 42% in adult 
(44% overall) of the relapsed leukemia developed from the major clone observed at ID, thus called successor 
leukemia. Only 7% of the pediatric (4% overall) were classified as novel leukemia, sharing no common mutations 
between ID and REL (see methods). The different evolution classes distributed evenly across subtypes, pediatric, 
adults, early and late relapses. One exception was the NH-HeH group with an underrepresentation of the succes-
sor (n = 2) and predominance of precursor phenotypes (n = 7) and one novel leukemia (n = 1).
We identified FLT3, JAK2 and RAS mutations as ‘volatile’ in the sense that the rise and fall of the clones con-
taining such mutations is notorious (Fig. 1b). Particularly RAS mutations have been reported as subclonal39. In 
our cohort five patients had stable NRAS mutations, meanwhile other five NRAS mutations were observed either 
only at ID or REL. Opposed to those ‘volatile’ mutations were TP53, KMT2D, CREBBP and PAX5 lesions, whose 
occurrence was either (re-)appearing or even rising into a major clone at relapse (Fig. S4). Recurrent stable amino 
acid changes were identified in CRLF2 (n = 5 patients, F232C, all Ph-like) and PAX5 P80R (n = 2). We observed 
novel recurring amino acid changes in the cancer-related genes ZEB2 H1038R (n = 3) and PTPN11 S502L (n = 2; 
Fig. 1b; Fig. S4).
To explore clonal hierarchies, we tracked co-occurrence of mutated genes and mutations occurring recur-
rently in the same or a descendant clone previously calculated for each individual patient (Figs S5–6; Table S5a). 
Figure 1. The clonal evolution of BCP-ALL patients reveal volatile and stable gene mutations. (a) The left and 
middle plot shows the mutation counts (y-axis) categorized into different mutational evolution (x-axis). The bar 
in black shows the stable mutations that were detected in both ID and REL over 10% variant allele frequency 
(VAF). The green bar shows mutations, which were only detected in ID and disappeared in REL, followed by 
the yellow bar, which shows mutations that dropped from over 10% VAF in ID to under 10% VAF in REL. The 
light blue bar shows the amount of mutations, which were increasing VAF from subclonal levels (under 10%), 
whereas the last bar reflects the mutations what were only detected in REL over 10% VAF. (b) The mutation 
count (y-axis) of the most recurrent genes (x-axis) and their categorization of the clonal evolution, maintaining 
the color scheme from (a). The right-hand plot the same information for recurrent amino acid substitutions 
by missense mutations with inverted axes. (c) The network shows mutations occurring together in the same 
and/or in a subsequent clone: the observed mutations (amount in gene nodes) are connected by the arrows. 
The number in the arrow shows how many times the mutations occurred in the same or a descending clone. 
Relations between mutations associated exclusively with molecular subgroups are highlighted by the ellipses 
and labels of the defined subgroups.
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We subsequently screened the clonal evolutions for subgroup specificity: Patients with TBL1XR1 mutations 
(n = 2; DUX4 subtype) also acquired ZEB2 mutations in a later clone. The ZNF483 (n = 3; Ph-like subtype) muta-
tions associated to the Ph-like subtype is novel and only occurred with an IKZF1 mutation background. The 
co-occurrence of RB1 and TP53 mutations have been exclusively observed in the LH patients (Fig. 1c). While 
some evolutionary paths of the mutations can be attributed to a genomic subgroup (highlighted in Fig. 1c), the 
overall pattern remains heterogeneous.
Novel alterations in chromatin modifiers and metabolic genes define BCP-ALL relapse. At 
relapse we identified significantly more mutations as compared to ID (adult median mutations per sample: 16 at 
REL vs 13.5 at ID; pediatric median: 19.5 at REL vs 10 at ID, respectively; Wilcoxon signed-rank test p-values for 
pediatric and adult samples: 6.37e-05/1.14e-03). Importantly, lesions we identified as preferentially occurring at 
relapse including non-silent mutations and copy-number losses affected 80% of all patients (n = 40; Fig. 2a and 
Table S5b). These altered genes could be attributed to functions in epigenetic regulation, metabolism, or are asso-
ciated with the TP53 pathway. Importantly, protein-protein interactions revealed that the altered metabolism and 
chromatin-modifying enzymes were tightly intertwined in their functions (Fig. S7).
We identified novel relapse-specific mutations in FPGS and ABGL1. Both genes showed relapse-specific 
lesions (n = 4 each) and stable losses (n = 3; Fig. 2a). FPGS is involved in the methotrexate metabolism through 
its function in glutamylation, which has been shown in a non-leukemic context40. Both patients have a muta-
tion in or close-by the annotated Mur-ligase domain (IPR036615) related to ATP-binding and ligase activity 
(Fig. 2b). ATP/GTP Binding Protein Like 1 (AGBL1), a glutamate decarboxylase, is the second gene bearing novel 
relapse-specific mutations, which is involved in the posttranscriptional glutamylation modifications, similar to 
FPGS. The observed mutations are located within and immediately downstream of the carboxypeptidase domain 
(Peptidase M14; IPR000834; Fig. 2b).
Figure 2. Relapse-specific alteration events of the BCP-ALL patients reveal enrichment of metabolism and 
chromatin modifier genes. (a) Shows relapse-specific mutations and copy number losses. Genes, which had at 
least one relapse-specific mutation, were selected for their implication in cancer or resistance mechanism. Genes 
(n = 21) have been classified into three the categories: metabolism, chromatin modifier and TP53 + others. 
The plot shows that 40 out of 50 (80%) patients have at least one relapse-specific alteration. (b) The relapse-
specific missense mutation metabolism-related genes FPGS and AGBL1 are shown in the amino acid sequence. 
Domains have been obtained from InterPro.
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Chemokines, interleukins and NF-kB up-regulation characterize the gene expression signature 
in DUX4 relapse samples. In addition to mutational alterations acquired at relapsed we investigated also 
transcriptional changes that contribute to recurrence of the disease. As the molecular subgroups are defined by 
specific expression signatures, we assayed relapse-specific expression patterns within the three largest subgroups 
separately. When comparing DUX4 ID to DUX4 REL samples, we observed 1291 (q-value < 0.1; Table S6a) pro-
tein coding genes as differentially expressed (Fig. 3a). No significantly deregulated genes were found comparing 
Ph-like ID to REL or comparing NH-HeH ID to REL samples.
A gene set over-representation of the specific DUX4 relapse-signature revealed that chemotaxis and cytokine 
interactions were strongly deregulated, many of them over-expressed in relapse compared to the corresponding 
DUX4 ID samples (Fig. 3b; Table S6b). Amongst the many up-regulated chemokines and interleukins, we found 
CCL2, CCL20, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, CXCL1, CXCL2, IL1R1, IL1R2, IL1RN, IL3, 
IL4I1, IL6 and IL8. Besides this, TNF-signaling and TOLL-like receptor, NF-kB-signaling and cellular response 
to interleukin-1 were over-represented terms in DUX4-REL.
Figure 3. DUX4 relapse-specific gene expression, regulation and pathway analyses reveal a chemokine-driven 
gene signature. (a) Shows the genes involved in the pathways and GO-terms enriched in REL compared to 
ID (n = 11; ID n = 12) of the DUX4 subtype that are annotated to an enriched pathway in subfigure (b). The 
heatmap is clustered by columns and rows (euclidean median hierarchical clustering), represented by the color-
coded bars on the left. The expression data show gene-centered fold changes of log2 TPM. (b) Relapse-specific 
expression signature pathways in the DUX4 subtype. Pathways of interest have been labeled and the edges 
between the nodes that represent pathways and GO-terms indicate that they share common genes. The FIPlugin 
for Cytoscape has been used to cluster the network. The resulting clusters are designated by node colors and 
with labels ranging from M0 to M6. (c) GSEA plots for Reactome pathways IL-10 Signaling and Chemokine 
Receptors. The strong up-regulation of both of these and other pathways corroborate the results in (a,b).
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A GSEA analysis confirmed multiple interleukin signaling, TOLL-Like and chemokine receptor gene sets as 
up-regulated (Fig. 3c; Table S6c). The chemokine ligand CCL2, Interleukin 8 (IL8) and the PDFGB gene were all 
amongst the top 30 up-regulated genes. CCL2 and IL8 are established targets of the NF-kB pathway. Regarding 
NF-kB-signaling, we observed that the genes NFKBIA, NFKB1, NFKB2 and NFKBID were all up-regulated at 
DUX4 REL and the GSEA results delivered various up-regulated NF-kB Reactome pathways in DUX4-REL. 
CAMK2A, a gene related to NF-kB-activation and has been demonstrated to act anti-apoptotic in cancer 
stem-like cells, is the third-most up-regulated gene at DUX4-REL41.
Proteomics identifies up-regulation of metabolic pathways at relapse. With this study, we intro-
duce the first comprehensive MASS-Spec proteome data set for relapsed BCP-ALL. We successfully quantified 
the expression of 1460 proteins across the 51 ID and REL samples from 36 patients, which had sufficient pro-
tein quality and quantity yielding high quality read-outs (Table S7a,b). De-regulated proteins at REL identified 
enrichment of proteins specifically involved in metabolic pathways including Glycolysis, Gluconeogenesis and 
the Pentose Phosphate Pathway (PPP; Fig. 4a; Table 2). The proteins GPI (Glycolysis), PGD and TKT (PPP) were 
concordantly up-regulated at relapse on protein abundance as well as mRNA transcript levels in over 50% of the 
samples (Figs 4b and S8). These two pathways, including the proteins G6PD, PGK1, GPI, PGD, and TKT, were 
particularly up-regulated in Ph-like relapse samples (Fig. S9).
Correlating specific genetic lesions with differential protein expression at relapse, we detected 310 proteins sig-
nificantly altered in TP53 mutated cases. We found that several PPP proteins described above to be up-regulated 
at relapse, show a significant up-regulation in TP53 mutated compared to TP53 wild type cases, linking TP53 
mutations with activation of the Glycolysis and PPP at relapse. PGD and TKT were highly expressed in TP53 
mutated samples (p-value < 0.01), while G6PD (p = 0.12) and TALDO1 (p = 0.07) display clear tendencies 
(Fig. 4c).
Discussion
Relapse remains a major source of morbidity and mortality in BCP-ALL patients. To characterize the genomic 
basis and functional context of BCP-ALL relapse, we applied a multi-omics approach on matched diagnosis and 
relapse samples from pediatric and adult patients (n = 50) lacking well-studied recurrent cytogenetically detecta-
ble chromosomal rearrangements BCR-ABL1, KMT2A-AFF1, ETV6-RUNX1, TCF3-PBX1.
The samples were allocated into recently described subgroups as defined by drivers including fusion genes or 
ploidy patterns revealing specific gene expression and DNA methylation profiles. Said patterns were stable in all 
Figure 4. Proteomics of BCP-ALL relapse. (a) The heatmap shows the proteins that are significantly 
up-regulated at REL. Proteins of the Phosphate Pentose pathway (PPP) and Glycolysis pathway, both 
overrepresented pathways at REL, are indicated at the right side of the heatmap by a P or G, respectively. The 
heatmap has been hierarchically clustered (top and right side representations in grey) using Gitools58. (b) Shows 
expression change of four metabolic proteins at ID and REL. If the net increase in expression is positive, the 
line is shown in red, otherwise in blue. (c) The box plots show protein expression levels of the members of the 
PPP as presented in the heatmap in (a), itemized by TP53 wild type (wt; n = 44) and TP53 sequence mutations 
(mut; n = 7). The significances are represented by the stars next to the protein name as follows: 1 star (*): 
0.05 ≥ p > 0.01, 2 stars (**): 0.01 ≥ p > 0.001.
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patients between ID and REL despite loss and acquisition of genetic lesions over extended time periods (max-
imum time to relapse: 8.6 years) and under the selective pressure of intensive chemotherapy. This supports the 
concept of driver alterations as founding lesions, which define a constant subgroup-specific biological framework 
for the individual disease42.
Analyzing acquired relapse-specific genomic alterations, we observed a high frequency of genes related to 
nucleotide metabolism, which has previously shown to be a key mechanism for resistance in leukemia. E.g. 
NT5C216 and PRPS125 have shown to promote resistance to purine analogue treatments, both also mutated within 
our cohort. We identified novel missense mutations p.G417E, p.P367L and p.P347S in two pediatric patients in 
the gene FPGS, which has been implicated in the resistance to methotrexate40. The majority of these alterations 
were either acquired at relapse or developed from a subclone, supporting a role in drug resistance mechanisms. 
In addition, we reveal novel relapse-acquired alterations in four patients were identified in the ATP/GTP-binding 
protein-like 1 gene AGBL1, including the two missense mutations p.G813R and p.R965K in two pediatric patients. 
AGBL1 is a member of the cytosolic carboxypeptidase family, which catalyze the decarboxylation of polyglutam-
ylated proteins43. Polyglutamylation is essential for the methotrexate activation and intracellular retention. Thus, 
alterations in AGBL1 might affect the activity of methotrexate. Mutations on both proteins (FPGS and AGBL1) 
are within annotated functional domains (Mur-ligase and hydropeptidase) and the immediate neighborhood, 
but the absence of protein structures limits the interpretation of the exact mode of action. While the protocols of 
treatment were very similar for both pediatric and adult patients, FPGS and AGBL1, as well as mutations in genes 
with critical functions in response to purine analogues (NT5C2 and PRPS1) or steroids (NR3C1) occurred exclu-
sively in pediatric relapse patients. Adult patients on the other hand showed a higher likeliness to accumulate 
more mutations in chromatin remodeling factors (e.g. CREBBP, KMT2D, ATRX, SETD2; Fig. 2).
In addition to metabolism-related mutations, chromatin-remodeling factors were frequently altered 
at relapse44. Acquired alterations included the transcriptional coactivator CREBBP, involved in glucocor-
ticoid responsiveness23, and the histone methyl-transferases KMT2D, EZH2, and SETD2. We show that 
the chromatin-remodeling factors and the metabolic proteins are tightly connected when mapped on a 
protein-protein interaction network44 (Fig. S7b). Together, alterations in both nucleotide metabolism genes and 
epigenetic regulators may cooperate in escape mechanisms, fostering chemo-resistant relapse.
So far, clonal plasticity and evolutional changes have been nearly exclusively studied on the genomic level. 
Here we show that relapse-specific changes are not restricted to the highlighted genetic alterations, but tran-
scriptional deregulation on the mRNA as well as protein level contribute to leukemic evolution without losing 
their BCP-ALL subgroup-specific identity. We defined a novel relapse-associated gene expression signature for 
DUX4 leukemias. While DUX4 is not expressed in normal B-cells, the DUX4-translocation has been shown to 
impair its normal DNA-binding in leukemic cells45, which in our cohort results in deregulated pathways includ-
ing NF-kB-signaling, chemokine/chemotaxis. Chemokines and interleukins were markedly up-regulated in the 
DUX4 relapse as our pathway and gene set enrichment analyses (GSEAs) showed. These results hint to an involve-
ment of the microenvironment contributing to leukemic relapse in DUX4 patients, particularly as the chemokine 
signature play a central role in relapsed leukemia46–48. The cytokines with the most prominent relapse-specific 
upregulation in DUX4 are all synthesized by monocytes. Analysis of corresponding surface marker mRNA 
expression revealed that DUX4 samples acquired CD14 expression at relapse in 7 of 11 cases (>2.5-fold increase 
from ID expression level) while the remaining 4 cases retained a stable CD14 expression from ID to relapse 
(<1.5-fold change). In addition monocytic differentiation factors CEBPA and CEBPB were upregulated in DUX4 
relapse samples (data not shown). These data provide evidence that DUX4 ALL represent a switchALL phenotype 
and that relapse in DUX4 ALL occurs with monocytic differentiation, as previously shown for a small proportion 
of BCP-ALL49.
In addition, results from myoblasts cells have shown that expression of DUX4 leads to overexpression of 
chemotaxis-related genes and to a greater migration potential by CXCR450. CXCR4 and chemotaxis genes in 
DUX4-translocated leukemia may contribute and enhance leukemia-stroma interactions facilitating DUX4 
blasts to survive treatment. Additionally, CAMK2A, the third most up-regulated gene at DUX4 relapse, acts as 
an anti-apoptosis regulator by activating NF-kB in metabolic stress-resistant cancer stem cells41. The prominent 
up-regulation the NF-kB pathway targets CCL2 and IL8 further hint at a crucial involvement of the pathway.
The analysis matched proteomics and genomics data for BCP-ALL is yet unexplored territory51 as the 
small size of the B-cell precursor blasts and the material- and time-intensive nature of MASS-SPEC render the 
Gene P-value Molecules (Proteins)
Glycolysis I 0.000227 ALDOA, ALDOC, GPI, PGAM1, PGK1, PKM
Gluconeogenesis I 0.000227 ALDOA, ALDOC, GPI, MDH1, PGAM1, PGK1
Pentose Phosphate Pathway 0.001333 G6PD, PGD, TALDO1, TKT
CDP-diacylglycerol Biosynthesis I 0.005917 AGPAT5, CDS2, LPCAT3, MBOAT7
Phosphatidylglycerol Biosynthesis II (Non-plastidic) 0.006806 AGPAT5, CDS2, LPCAT3, MBOAT7
EIF2 Signaling 0.009853 RPL14, RPL17, RPL23A, RPL3, RPL36, RPL7, RPL8, RPS17
Sirtuin Signaling Pathway 0.010153 ACLY, G6PD, H1FX, LDHB, NAMPT, PCK2, PGAM1, PGK1, TIMM9
Adenine and Adenosine Salvage I 0.010567 APRT, PNP
Antigen Presentation Pathway 0.013300 HLA-DRA, HLA-DRB1, TAP2, TAPBP
Pentose Phosphate Pathway (Oxidative Branch) 0.039164 G6PD, PGD
Table 2. Top 10 canonical Ingenuity pathways for the differentially expressed proteins at BCP-ALL relapse.
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acquisition of homogeneous BCP-ALL proteome challenging. We here provide novel insights into the proteomic 
consequences by dissecting the relapse-specific proteomics data set. We unraveled that proteins involved in glyc-
olysis (GPI, PGK1, PGAM1) and PPP (G6PD, PGD, TKT, TALDO1) are specifically up-regulated at relapse, par-
ticularly in non-DUX4 samples. Multiple adaptations have been identified in malignant cells for increased energy 
demands and oxidative stress imposed by oncogenic transformation52. In BCP-ALL, frequently deleted B cell 
transcription factors (IKZF1, PAX5) have been characterized as gatekeepers toward malignant transformation 
through limiting the energy supply below a minimum required threshold53. Moreover, BCP-ALL cells critically 
depend on the PPP to salvage oxidative stress27. Given that oxidative stress is a major effector of chemotherapy, it 
seems likely that our observation of an increased PPP at BCP-ALL relapse represents an adaptation and a resist-
ance mechanism to first line chemotherapy. Beyond its function in energy supply, glycolysis has a major role in 
providing metabolic intermediates for the biosynthesis of cellular components required during proliferation54. 
Thus, an increase in glycolysis in relapsed BCP-ALL possibly reflects an adaptation to the increased demand for 
cellular building blocks for the rapid expansion of chemoresistant relapse clones. Interestingly, in our cohort the 
up-regulation of PPP proteins was not only linked to relapse but also to the presence of TP53 mutations. Given 
that mutant TP53 can also exert gain-of-functions55, our observation strengthens clinical evidence of preclinical 
models showing that TP53 promotes PPP through transcriptional activation of its target gene TIGAR27,56.
In addition to the dissection of relapse-specificity identified at different levels (DNA, RNA, protein changes), 
our study provides a comprehensive analysis of pediatric and adult patients (Table S8). Data acquisition was 
performed using the same platforms and analysis pipelines, allowing for direct comparison with all patients were 
treated based on a pediatric-inspired protocols. With this approach, we show that in adults unfavorable features 
were enriched, such as lower frequency of DUX4 fusions and a tendency towards a higher TP53 mutations fre-
quency. Additionally we show that the relapse-specific mutations reveal a chromatin modifier profile in adults 
whereas a metabolic profile was prominent in relapsed pediatric patients.
Moreover, we explored molecular differences between early or late relapses and identified enrichment of 
CDKN2A/B deletions as well as novel alterations (predominantly deletions) in the gene protein tyrosine phos-
phatases receptor type D (PTPRD), specifically in early relapse (7/25 early vs. 0/25 late relapse). The co-deletion of 
PTPRD, a candidate tumor suppressor, and CDKN2A has been reported to accelerate tumorigenesis, facilitating 
an early escape57.
Conclusion
We conclude that alterations in metabolic pathways are one major hallmarks of relapsed leukemia as (a) meta-
bolic genes were frequently mutated on the genomic level and confer resistance to chemotherapeutic agents and 
(b) our proteomic signature defines glycolysis and PPP as key deregulated pathways in relapsed BCP-ALL. We 
also provide novel insights into clonal evolution, age and relapse-specific molecular alterations and show that 
the molecular BCP-ALL subtype eclipses age and treatment. The pediatric-dominated DUX4 relapse-specific 
signature is characterized by chemokine interaction, interleukin signaling and NF-kB pathway extends also to 
the adult. We think that the presented results contribute to the better understanding of relapsed ALL in adult and 
pediatric patients facilitating tailored therapeutic concepts.
Data Availability
The analysed and primary datasets supporting the conclusions of this article are available in the and at the Euro-
pean Genome-phenome Archive repository under the accession number EGAS00001002856.
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